Tempus AI, Inc. $TEM Shares Sold by Venture Visionary Partners LLC

Venture Visionary Partners LLC cut its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 20.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,474 shares of the company’s stock after selling 11,894 shares during the period. Venture Visionary Partners LLC’s holdings in Tempus AI were worth $2,685,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TEM. Royal Bank of Canada grew its stake in Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new position in Tempus AI in the first quarter worth about $116,000. Prudential Financial Inc. acquired a new position in Tempus AI in the second quarter worth about $276,000. Russell Investments Group Ltd. grew its stake in Tempus AI by 21.3% in the second quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Tempus AI by 2,926.6% in the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TEM shares. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target for the company. HC Wainwright decreased their price target on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Wolfe Research started coverage on Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. TD Cowen lifted their price target on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $68.64.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $52.32 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The firm’s 50-day moving average price is $49.42 and its two-hundred day moving average price is $56.51. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32. The stock has a market capitalization of $9.40 billion, a P/E ratio of -30.42 and a beta of 3.64.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter last year, the company posted ($0.24) earnings per share. Tempus AI’s revenue was up 36.1% on a year-over-year basis. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Insider Transactions at Tempus AI

In related news, EVP Andrew Polovin sold 8,703 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the sale, the executive vice president directly owned 128,215 shares in the company, valued at $5,650,435.05. This trade represents a 6.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 4,116 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the completion of the sale, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. This represents a 5.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 558,557 shares of company stock valued at $26,611,939 over the last ninety days. Insiders own 24.26% of the company’s stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.